Literature DB >> 25267756

Should we replace dexamethasone, cytarabine, and cisplatin for relapsed lymphoma?

Christian Gisselbrecht1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25267756     DOI： 10.1200/JCO.2014.56.6802

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Authors:  E Van Den Neste; N Schmitz; N Mounier; D Gill; D Linch; M Trneny; N Milpied; J Radford; N Ketterer; O Shpilberg; U Dührsen; D Ma; J Brière; C Thieblemont; G Salles; C H Moskowitz; B Glass; C Gisselbrecht
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

2.  Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy.

Authors:  Stefano Di Biase; Hong Seok Shim; Kyung Hwa Kim; Manlio Vinciguerra; Francesca Rappa; Min Wei; Sebastian Brandhorst; Francesco Cappello; Hamed Mirzaei; Changhan Lee; Valter D Longo
Journal:  PLoS Biol       Date:  2017-03-30       Impact factor: 8.029
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.